Table 2.
Baseline characteristics of the study cohort (n = 59)
| Parameter | Value ± SD (mean) |
|---|---|
| Age, years, mean ± SD | 46 ± 14 |
| Female, n (%) | 11 (18.6) |
| Renal disease (KDIGO 2012), n (%) | 15 (25.4) |
| Diabetes mellitus type II, n (%) | 11 (18.6) |
| Arterial hypertension, n (%) | 20 (33.9) |
| BMI, kg/m2, mean ± SD | 27 ± 4 |
| ECG on admission | |
| Sinus rhythm, n (%) | 47 (79.7) |
| Atrial fibrillation, n (%) | 12 (20.3) |
| Left bundle brunch block, n (%) | 11 (18.6) |
| Atrial fibrillation during hospital stay, n (%) | 15 (25.4) |
| Paroxysmal, n (%) | 7 (11.9) |
| Persistent, n (%) | 7 (11.9) |
| Permanent, n (%) | 1 (1.7) |
| Ventricular arrhythmias during hospital stay, n (%) | 11 (18.6) |
| Sustained VT, n (%) | 9 (15.3) |
| VF, n (%) | 2 (3.4) |
| Heart rate at diagnosis, b.p.m., mean ± SD | 88 ± 24 |
| LVEF at diagnosis, %, mean ± SD | 32 ± 15 |
| LVEDD at diagnosis, mm, mean ± SD | 62 ± 9 |
| TAPSE, mean ± SD, mm | 19 ± 5 |
| NYHA at diagnosis | |
| I, n (%) | 11 (18.6) |
| II, n (%) | 22 (37.3) |
| III, n (%) | 20 (33.9) |
| IV, n (%) | 4 (6.8) |
| TnT‐hs on admission, ng/L, mean ± SD | 193 ± 493 |
| NT‐proBNP at diagnosis, ng/L, mean ± SD | 7102 ± 13 168 |
| Medication at discharge | |
| Beta‐blockers, n (%) | 56 (94.9) |
| ACE inhibitors, n (%) | 54 (91.5) |
| Angiotensin receptor blockers, n (%) | 3 (5.1) |
| Aldosterone antagonists, n (%) | 47 (79.7) |
| Nephrolysin inhibitors, n (%) | 1 (1.7) |
| Antiviral therapy, n (%) | 5 (8.5) |
| Immunosuppressive therapy, n (%) | 15 (25.4) |
ACE, angiotensin‐converting enzyme; BMI, body mass index; ECG, electrocardiography; KDIGO, Kidney Disease Improving Global Outcomes; LVEDD, left ventricular end‐diastolic diameter; LVEF, left ventricular ejection fraction; NT‐proBNP, N‐terminal prohormone of brain natriuretic peptide; NYHA, New York Heart Association; SD, standard deviation; TAPSE, tricuspid annular plane systolic excursion; TnT‐hs, high‐sensitivity cardiac troponin‐T; VF, ventricular fibrillation; VT, ventricular tachycardia.